trending Market Intelligence /marketintelligence/en/news-insights/trending/rwjpjdablvpgd_6p6x75mq2 content esgSubNav
In This List

Anteo Diagnostics extends interim CEO's appointment

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Anteo Diagnostics extends interim CEO's appointment

Anteo Diagnostics Ltd. said Christopher Parker will remain as the company's interim CEO until June 30, 2019.

In April, Parker was appointed to the interim CEO post for an initial three-month period.

The contract extension will provide business continuity as the company executes its development strategy in the battery and diagnostic markets.

Australia-based Anteo Diagnostics is engaged in the development and commercialization of products for the life sciences, clinical diagnostics and bioseparations sectors.